A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study is being performed to investigate the potential for AZD5672 to affect the
electrical conduction pathways in the heart. AZD5672 will be compared against a drug
(moxifloxacin - a licensed antibiotic) known to have a detectable but safe change on the
electrical conduction of the heart.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Quintiles, Inc.
Treatments:
Fluoroquinolones Moxifloxacin N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide Norgestimate, ethinyl estradiol drug combination